浙江大学在《Cell Discovery》发文揭示肾透明细胞癌中的关键调控程序

2022-07-30 浙江大学医学院 网络

深入刻画ccRCC微环境中的细胞组成和基因组调控特征对于我们理解肿瘤致病机理和开发新的治疗策略具有重要意义。

浙江大学医学院附属第二医院泌尿外科文甲明和王博涵课题组和西湖大学谢琦课题组合作作为共通讯作者(文甲明为最后通讯作者)近日在《Cell Discovery》上发表题为Single-cell multiomics analysis reveals regulatory programs in clear cell renal cell carcinoma的研究论文,对ccRCC在单细胞水平进行了多维度的探索。这项研究整合了single-cell RNA-seq(scRNA-seq)和single-cell ATAC-seq (scATAC-seq)数据,描绘了ccRCC的转录组和表观基因组图谱,识别了在肿瘤细胞和多种免疫细胞中发挥重要作用的调控因子,进一步阐明了ccRCC的异质性并发现了潜在的治疗靶点。

肾透明细胞癌(clear cell renal carcinoma, ccRCC)是肾细胞癌中最常见和最具侵袭性的亚型。当前多种临床治疗策略,如靶向治疗和免疫治疗,仍然还无法很好地应对高度异质性的肿瘤微环境,所以在临床上并没有取得令人满意的治疗效果。深入刻画ccRCC微环境中的细胞组成和基因组调控特征对于我们理解肿瘤致病机理和开发新的治疗策略具有重要意义。

近年来,单细胞测序技术飞速发展,已经能够检测出单个细胞的基因转录表达和表观基因组调控等多种维度的信息。这种单细胞水平的多维度信息能够以更高分辨率和更广的视角来帮助解析组织发育和疾病发生发展的关键因素。最近,多个研究团队针对健康的肾脏组织,联合single-nucleus RNA-seq和single-nucleus ATAC-seq技术刻画了在肾脏发育过程基因表达和表观基因组调控的特征,并识别了驱动肾小管细胞分化和近端小管上皮细胞亚群转换的关键调控因子。然而,ccRCC的单细胞多维度视角目前还没有被打开。

该研究对ccRCC患者的肿瘤组织进行了配对的scRNA-seq和scATAC-seq测序,分别获得了38,097和21,272个单细胞。通过单细胞数据分析,识别了多种淋巴细胞和髓系细胞亚群。联合ccRCC标志基因CA9和拷贝数变异特征,在两种数据类型中各鉴定出了一个肿瘤细胞群体。总的来说,免疫细胞是ccRCC微环境中主要的细胞群体(>70%),肿瘤细胞只占不到10%。

通过设计严格的筛选策略,并结合TCGA-KIRC生存数据,研究人员识别了4个肿瘤细胞特异富集且显著和病人更差预后生存相关的转录因子(HOXC5, VENTX, ISL1和OTP)。基于scATAC-seq捕获到的染色质开放信息,研究人员进一步识别出了这些转录因子的下游靶基因并构建了其表观调控网络。分析发现,这些转录因子的靶基因显著富集于低氧和细胞增殖信号通路,且包含多个在肿瘤细胞群体中显著高表达的基因(FXYD2和CRYAB)。此外,结合先前的scRNA-seq数据,研究人员发现这些靶基因特异性地富集于肿瘤细胞群体。

为了进一步调查这些调控因子对肿瘤细胞的影响,研究人员分别在肾细胞癌细胞系和异种移植小鼠肿瘤模型中分别敲低这几个转录因子,发现能够显著降低肿瘤细胞的生长。同时结合小分子化合物扰动数据库-LINCS,研究人员筛选出了2个已被美国食品药品监督管理局(FDA)批准用于疾病治疗的药物(homoharringtonine和mitotane)能够明显降低HOXC5, ISL1和VENTX的表达,并在两个肾细胞癌细胞系进行了进一步的验证。

此外,研究人员也刻画了对各个免疫细胞亚群的转录程序和表观特征,并在肿瘤细胞和免疫细胞亚群间识别出了多对具有潜在临床意义的配体-受体互作对。综上所述,该研究描绘了 ccRCC 的单细胞转录组和表观基因组图谱,识别了肿瘤细胞特异的基因转录和表观调控程序,为设计更有效的治疗策略提供了新的线索。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2010080, encodeId=cb31201008015, content=<a href='/topic/show?id=6d13948196c' target=_blank style='color:#2F92EE;'>#透明细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94819, encryptionId=6d13948196c, topicName=透明细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f1167, createdName=wmr111, createdTime=Tue Jan 31 19:30:07 CST 2023, time=2023-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013934, encodeId=82fa2013934ac, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Mon Sep 26 15:30:07 CST 2022, time=2022-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1962806, encodeId=3d071962806be, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Sep 29 14:30:07 CST 2022, time=2022-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784352, encodeId=e2aa1e84352f2, content=<a href='/topic/show?id=96f65992e6' target=_blank style='color:#2F92EE;'>#Discovery》#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5992, encryptionId=96f65992e6, topicName=Discovery》)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec53439, createdName=zhty5337, createdTime=Tue Feb 07 12:30:07 CST 2023, time=2023-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1872477, encodeId=90f018e2477d1, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Jun 11 04:30:07 CST 2023, time=2023-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783738, encodeId=b73a1e8373863, content=<a href='/topic/show?id=d195513038' target=_blank style='color:#2F92EE;'>#cover#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5130, encryptionId=d195513038, topicName=cover)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Fri Aug 26 15:30:07 CST 2022, time=2022-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1979356, encodeId=64d819e93565d, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Mon Feb 06 19:30:07 CST 2023, time=2023-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1745706, encodeId=21c11e4570634, content=<a href='/topic/show?id=73826552320' target=_blank style='color:#2F92EE;'>#浙江大学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65523, encryptionId=73826552320, topicName=浙江大学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c35635545425, createdName=一闲, createdTime=Fri Oct 14 11:30:07 CST 2022, time=2022-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587951, encodeId=cfb8158e95157, content=<a href='/topic/show?id=cb1e1006ebd' target=_blank style='color:#2F92EE;'>#ISC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10067, encryptionId=cb1e1006ebd, topicName=ISC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173417575755, createdName=yankaienglish, createdTime=Fri Jul 29 01:30:07 CST 2022, time=2022-07-29, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2010080, encodeId=cb31201008015, content=<a href='/topic/show?id=6d13948196c' target=_blank style='color:#2F92EE;'>#透明细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94819, encryptionId=6d13948196c, topicName=透明细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f1167, createdName=wmr111, createdTime=Tue Jan 31 19:30:07 CST 2023, time=2023-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013934, encodeId=82fa2013934ac, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Mon Sep 26 15:30:07 CST 2022, time=2022-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1962806, encodeId=3d071962806be, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Sep 29 14:30:07 CST 2022, time=2022-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784352, encodeId=e2aa1e84352f2, content=<a href='/topic/show?id=96f65992e6' target=_blank style='color:#2F92EE;'>#Discovery》#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5992, encryptionId=96f65992e6, topicName=Discovery》)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec53439, createdName=zhty5337, createdTime=Tue Feb 07 12:30:07 CST 2023, time=2023-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1872477, encodeId=90f018e2477d1, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Jun 11 04:30:07 CST 2023, time=2023-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783738, encodeId=b73a1e8373863, content=<a href='/topic/show?id=d195513038' target=_blank style='color:#2F92EE;'>#cover#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5130, encryptionId=d195513038, topicName=cover)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Fri Aug 26 15:30:07 CST 2022, time=2022-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1979356, encodeId=64d819e93565d, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Mon Feb 06 19:30:07 CST 2023, time=2023-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1745706, encodeId=21c11e4570634, content=<a href='/topic/show?id=73826552320' target=_blank style='color:#2F92EE;'>#浙江大学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65523, encryptionId=73826552320, topicName=浙江大学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c35635545425, createdName=一闲, createdTime=Fri Oct 14 11:30:07 CST 2022, time=2022-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587951, encodeId=cfb8158e95157, content=<a href='/topic/show?id=cb1e1006ebd' target=_blank style='color:#2F92EE;'>#ISC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10067, encryptionId=cb1e1006ebd, topicName=ISC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173417575755, createdName=yankaienglish, createdTime=Fri Jul 29 01:30:07 CST 2022, time=2022-07-29, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2010080, encodeId=cb31201008015, content=<a href='/topic/show?id=6d13948196c' target=_blank style='color:#2F92EE;'>#透明细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94819, encryptionId=6d13948196c, topicName=透明细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f1167, createdName=wmr111, createdTime=Tue Jan 31 19:30:07 CST 2023, time=2023-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013934, encodeId=82fa2013934ac, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Mon Sep 26 15:30:07 CST 2022, time=2022-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1962806, encodeId=3d071962806be, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Sep 29 14:30:07 CST 2022, time=2022-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784352, encodeId=e2aa1e84352f2, content=<a href='/topic/show?id=96f65992e6' target=_blank style='color:#2F92EE;'>#Discovery》#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5992, encryptionId=96f65992e6, topicName=Discovery》)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec53439, createdName=zhty5337, createdTime=Tue Feb 07 12:30:07 CST 2023, time=2023-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1872477, encodeId=90f018e2477d1, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Jun 11 04:30:07 CST 2023, time=2023-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783738, encodeId=b73a1e8373863, content=<a href='/topic/show?id=d195513038' target=_blank style='color:#2F92EE;'>#cover#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5130, encryptionId=d195513038, topicName=cover)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Fri Aug 26 15:30:07 CST 2022, time=2022-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1979356, encodeId=64d819e93565d, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Mon Feb 06 19:30:07 CST 2023, time=2023-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1745706, encodeId=21c11e4570634, content=<a href='/topic/show?id=73826552320' target=_blank style='color:#2F92EE;'>#浙江大学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65523, encryptionId=73826552320, topicName=浙江大学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c35635545425, createdName=一闲, createdTime=Fri Oct 14 11:30:07 CST 2022, time=2022-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587951, encodeId=cfb8158e95157, content=<a href='/topic/show?id=cb1e1006ebd' target=_blank style='color:#2F92EE;'>#ISC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10067, encryptionId=cb1e1006ebd, topicName=ISC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173417575755, createdName=yankaienglish, createdTime=Fri Jul 29 01:30:07 CST 2022, time=2022-07-29, status=1, ipAttribution=)]
    2022-09-29 维他命
  4. [GetPortalCommentsPageByObjectIdResponse(id=2010080, encodeId=cb31201008015, content=<a href='/topic/show?id=6d13948196c' target=_blank style='color:#2F92EE;'>#透明细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94819, encryptionId=6d13948196c, topicName=透明细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f1167, createdName=wmr111, createdTime=Tue Jan 31 19:30:07 CST 2023, time=2023-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013934, encodeId=82fa2013934ac, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Mon Sep 26 15:30:07 CST 2022, time=2022-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1962806, encodeId=3d071962806be, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Sep 29 14:30:07 CST 2022, time=2022-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784352, encodeId=e2aa1e84352f2, content=<a href='/topic/show?id=96f65992e6' target=_blank style='color:#2F92EE;'>#Discovery》#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5992, encryptionId=96f65992e6, topicName=Discovery》)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec53439, createdName=zhty5337, createdTime=Tue Feb 07 12:30:07 CST 2023, time=2023-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1872477, encodeId=90f018e2477d1, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Jun 11 04:30:07 CST 2023, time=2023-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783738, encodeId=b73a1e8373863, content=<a href='/topic/show?id=d195513038' target=_blank style='color:#2F92EE;'>#cover#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5130, encryptionId=d195513038, topicName=cover)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Fri Aug 26 15:30:07 CST 2022, time=2022-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1979356, encodeId=64d819e93565d, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Mon Feb 06 19:30:07 CST 2023, time=2023-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1745706, encodeId=21c11e4570634, content=<a href='/topic/show?id=73826552320' target=_blank style='color:#2F92EE;'>#浙江大学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65523, encryptionId=73826552320, topicName=浙江大学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c35635545425, createdName=一闲, createdTime=Fri Oct 14 11:30:07 CST 2022, time=2022-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587951, encodeId=cfb8158e95157, content=<a href='/topic/show?id=cb1e1006ebd' target=_blank style='color:#2F92EE;'>#ISC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10067, encryptionId=cb1e1006ebd, topicName=ISC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173417575755, createdName=yankaienglish, createdTime=Fri Jul 29 01:30:07 CST 2022, time=2022-07-29, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2010080, encodeId=cb31201008015, content=<a href='/topic/show?id=6d13948196c' target=_blank style='color:#2F92EE;'>#透明细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94819, encryptionId=6d13948196c, topicName=透明细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f1167, createdName=wmr111, createdTime=Tue Jan 31 19:30:07 CST 2023, time=2023-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013934, encodeId=82fa2013934ac, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Mon Sep 26 15:30:07 CST 2022, time=2022-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1962806, encodeId=3d071962806be, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Sep 29 14:30:07 CST 2022, time=2022-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784352, encodeId=e2aa1e84352f2, content=<a href='/topic/show?id=96f65992e6' target=_blank style='color:#2F92EE;'>#Discovery》#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5992, encryptionId=96f65992e6, topicName=Discovery》)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec53439, createdName=zhty5337, createdTime=Tue Feb 07 12:30:07 CST 2023, time=2023-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1872477, encodeId=90f018e2477d1, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Jun 11 04:30:07 CST 2023, time=2023-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783738, encodeId=b73a1e8373863, content=<a href='/topic/show?id=d195513038' target=_blank style='color:#2F92EE;'>#cover#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5130, encryptionId=d195513038, topicName=cover)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Fri Aug 26 15:30:07 CST 2022, time=2022-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1979356, encodeId=64d819e93565d, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Mon Feb 06 19:30:07 CST 2023, time=2023-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1745706, encodeId=21c11e4570634, content=<a href='/topic/show?id=73826552320' target=_blank style='color:#2F92EE;'>#浙江大学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65523, encryptionId=73826552320, topicName=浙江大学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c35635545425, createdName=一闲, createdTime=Fri Oct 14 11:30:07 CST 2022, time=2022-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587951, encodeId=cfb8158e95157, content=<a href='/topic/show?id=cb1e1006ebd' target=_blank style='color:#2F92EE;'>#ISC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10067, encryptionId=cb1e1006ebd, topicName=ISC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173417575755, createdName=yankaienglish, createdTime=Fri Jul 29 01:30:07 CST 2022, time=2022-07-29, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2010080, encodeId=cb31201008015, content=<a href='/topic/show?id=6d13948196c' target=_blank style='color:#2F92EE;'>#透明细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94819, encryptionId=6d13948196c, topicName=透明细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f1167, createdName=wmr111, createdTime=Tue Jan 31 19:30:07 CST 2023, time=2023-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013934, encodeId=82fa2013934ac, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Mon Sep 26 15:30:07 CST 2022, time=2022-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1962806, encodeId=3d071962806be, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Sep 29 14:30:07 CST 2022, time=2022-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784352, encodeId=e2aa1e84352f2, content=<a href='/topic/show?id=96f65992e6' target=_blank style='color:#2F92EE;'>#Discovery》#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5992, encryptionId=96f65992e6, topicName=Discovery》)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec53439, createdName=zhty5337, createdTime=Tue Feb 07 12:30:07 CST 2023, time=2023-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1872477, encodeId=90f018e2477d1, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Jun 11 04:30:07 CST 2023, time=2023-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783738, encodeId=b73a1e8373863, content=<a href='/topic/show?id=d195513038' target=_blank style='color:#2F92EE;'>#cover#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5130, encryptionId=d195513038, topicName=cover)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Fri Aug 26 15:30:07 CST 2022, time=2022-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1979356, encodeId=64d819e93565d, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Mon Feb 06 19:30:07 CST 2023, time=2023-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1745706, encodeId=21c11e4570634, content=<a href='/topic/show?id=73826552320' target=_blank style='color:#2F92EE;'>#浙江大学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65523, encryptionId=73826552320, topicName=浙江大学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c35635545425, createdName=一闲, createdTime=Fri Oct 14 11:30:07 CST 2022, time=2022-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587951, encodeId=cfb8158e95157, content=<a href='/topic/show?id=cb1e1006ebd' target=_blank style='color:#2F92EE;'>#ISC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10067, encryptionId=cb1e1006ebd, topicName=ISC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173417575755, createdName=yankaienglish, createdTime=Fri Jul 29 01:30:07 CST 2022, time=2022-07-29, status=1, ipAttribution=)]
    2022-08-26 yahu
  7. [GetPortalCommentsPageByObjectIdResponse(id=2010080, encodeId=cb31201008015, content=<a href='/topic/show?id=6d13948196c' target=_blank style='color:#2F92EE;'>#透明细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94819, encryptionId=6d13948196c, topicName=透明细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f1167, createdName=wmr111, createdTime=Tue Jan 31 19:30:07 CST 2023, time=2023-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013934, encodeId=82fa2013934ac, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Mon Sep 26 15:30:07 CST 2022, time=2022-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1962806, encodeId=3d071962806be, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Sep 29 14:30:07 CST 2022, time=2022-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784352, encodeId=e2aa1e84352f2, content=<a href='/topic/show?id=96f65992e6' target=_blank style='color:#2F92EE;'>#Discovery》#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5992, encryptionId=96f65992e6, topicName=Discovery》)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec53439, createdName=zhty5337, createdTime=Tue Feb 07 12:30:07 CST 2023, time=2023-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1872477, encodeId=90f018e2477d1, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Jun 11 04:30:07 CST 2023, time=2023-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783738, encodeId=b73a1e8373863, content=<a href='/topic/show?id=d195513038' target=_blank style='color:#2F92EE;'>#cover#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5130, encryptionId=d195513038, topicName=cover)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Fri Aug 26 15:30:07 CST 2022, time=2022-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1979356, encodeId=64d819e93565d, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Mon Feb 06 19:30:07 CST 2023, time=2023-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1745706, encodeId=21c11e4570634, content=<a href='/topic/show?id=73826552320' target=_blank style='color:#2F92EE;'>#浙江大学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65523, encryptionId=73826552320, topicName=浙江大学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c35635545425, createdName=一闲, createdTime=Fri Oct 14 11:30:07 CST 2022, time=2022-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587951, encodeId=cfb8158e95157, content=<a href='/topic/show?id=cb1e1006ebd' target=_blank style='color:#2F92EE;'>#ISC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10067, encryptionId=cb1e1006ebd, topicName=ISC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173417575755, createdName=yankaienglish, createdTime=Fri Jul 29 01:30:07 CST 2022, time=2022-07-29, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=2010080, encodeId=cb31201008015, content=<a href='/topic/show?id=6d13948196c' target=_blank style='color:#2F92EE;'>#透明细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94819, encryptionId=6d13948196c, topicName=透明细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f1167, createdName=wmr111, createdTime=Tue Jan 31 19:30:07 CST 2023, time=2023-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013934, encodeId=82fa2013934ac, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Mon Sep 26 15:30:07 CST 2022, time=2022-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1962806, encodeId=3d071962806be, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Sep 29 14:30:07 CST 2022, time=2022-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784352, encodeId=e2aa1e84352f2, content=<a href='/topic/show?id=96f65992e6' target=_blank style='color:#2F92EE;'>#Discovery》#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5992, encryptionId=96f65992e6, topicName=Discovery》)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec53439, createdName=zhty5337, createdTime=Tue Feb 07 12:30:07 CST 2023, time=2023-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1872477, encodeId=90f018e2477d1, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Jun 11 04:30:07 CST 2023, time=2023-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783738, encodeId=b73a1e8373863, content=<a href='/topic/show?id=d195513038' target=_blank style='color:#2F92EE;'>#cover#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5130, encryptionId=d195513038, topicName=cover)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Fri Aug 26 15:30:07 CST 2022, time=2022-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1979356, encodeId=64d819e93565d, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Mon Feb 06 19:30:07 CST 2023, time=2023-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1745706, encodeId=21c11e4570634, content=<a href='/topic/show?id=73826552320' target=_blank style='color:#2F92EE;'>#浙江大学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65523, encryptionId=73826552320, topicName=浙江大学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c35635545425, createdName=一闲, createdTime=Fri Oct 14 11:30:07 CST 2022, time=2022-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587951, encodeId=cfb8158e95157, content=<a href='/topic/show?id=cb1e1006ebd' target=_blank style='color:#2F92EE;'>#ISC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10067, encryptionId=cb1e1006ebd, topicName=ISC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173417575755, createdName=yankaienglish, createdTime=Fri Jul 29 01:30:07 CST 2022, time=2022-07-29, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=2010080, encodeId=cb31201008015, content=<a href='/topic/show?id=6d13948196c' target=_blank style='color:#2F92EE;'>#透明细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94819, encryptionId=6d13948196c, topicName=透明细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f1167, createdName=wmr111, createdTime=Tue Jan 31 19:30:07 CST 2023, time=2023-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013934, encodeId=82fa2013934ac, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Mon Sep 26 15:30:07 CST 2022, time=2022-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1962806, encodeId=3d071962806be, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Sep 29 14:30:07 CST 2022, time=2022-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784352, encodeId=e2aa1e84352f2, content=<a href='/topic/show?id=96f65992e6' target=_blank style='color:#2F92EE;'>#Discovery》#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5992, encryptionId=96f65992e6, topicName=Discovery》)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec53439, createdName=zhty5337, createdTime=Tue Feb 07 12:30:07 CST 2023, time=2023-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1872477, encodeId=90f018e2477d1, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Jun 11 04:30:07 CST 2023, time=2023-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783738, encodeId=b73a1e8373863, content=<a href='/topic/show?id=d195513038' target=_blank style='color:#2F92EE;'>#cover#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5130, encryptionId=d195513038, topicName=cover)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Fri Aug 26 15:30:07 CST 2022, time=2022-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1979356, encodeId=64d819e93565d, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Mon Feb 06 19:30:07 CST 2023, time=2023-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1745706, encodeId=21c11e4570634, content=<a href='/topic/show?id=73826552320' target=_blank style='color:#2F92EE;'>#浙江大学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65523, encryptionId=73826552320, topicName=浙江大学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c35635545425, createdName=一闲, createdTime=Fri Oct 14 11:30:07 CST 2022, time=2022-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587951, encodeId=cfb8158e95157, content=<a href='/topic/show?id=cb1e1006ebd' target=_blank style='color:#2F92EE;'>#ISC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10067, encryptionId=cb1e1006ebd, topicName=ISC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173417575755, createdName=yankaienglish, createdTime=Fri Jul 29 01:30:07 CST 2022, time=2022-07-29, status=1, ipAttribution=)]
    2022-07-29 yankaienglish

相关资讯

ASCO GU 2021: HIF-2α抑制剂Belzutifan在晚期肾透明细胞癌中初显疗效

Belzutifan(MK-6482)是一种小分子HIF-2α抑制剂,临床前研究已证实可诱导肾细胞癌模型的肿瘤消退,此前也报道了首个人类实体瘤的Ⅰ期研究。2021年ASCO GU大会口头报

Clin Cancer Res:MEDI0680联合杜瓦鲁单抗治疗晚期肾透明细胞癌

MEDI0680联合杜瓦鲁单抗在晚期透明细胞癌患者中的安全性和耐受性良好,但是与纳武单抗单药治疗相比,不能提高疗效

Lancet Oncol:转移性肾透明细胞癌的三种一线治疗方案的疗效和安全性

如何在纳武单抗加或不加伊匹单抗和VEGFR-TKI之间选择最有效的治疗转移性肾透明细胞癌的一线治疗方案

Eur Urol:评估两种起始剂量的乐伐替尼加依维莫司对肾细胞癌患者的安全性和有效性:一项随机的2期试验

评估了较低起始剂量的乐伐替尼是否具有与之相当的疗效,且能同时改善乐伐替尼加依维莫司治疗晚期RCC患者的耐受性。

JCO:帕博利珠单抗一线治疗进展期肾透明细胞癌患者一线治疗的ORR可达36.4%

帕博利珠单抗一线治疗进展期肾透明细胞癌(ccRCC)患者安全有效,且反应持久(ORR,36.4%; CR,3.6%; PR,32.7%)。

Clin Cancer Res:MEDI0680+Durvalumab vs 纳武单抗治疗晚期肾透明细胞癌

MEDI0680联合德瓦鲁单抗治疗晚期肾透明细胞癌的安全性和耐受性良好